| |
|
|
|
Xtalks, online
2023 -9-14
Neuroscience trials increasingly depend on non-clinical measures from early-stage development through pivotal trials. The introduction of diagnosis is done by gene, blood, cerebrospinal fluid (CSF) and imaging measures as well as accelerated approval with biomarker surrogate endpoints. Navigating this new landscape requires an integrated contract research organization (CRO) strategy for the development program and trials at each stage of the process.
In this webinar, the featured speakers discuss new key measures relevant to neuroscience trials. They explore how to integrate and manage imaging and liquid biomarkers in neuroscience therapeutic product development. Collaboration and cooperation between the CRO and laboratories providing specialized services for imaging and biochemical assays are critical to delivering high-quality, regulatory-compliant endpoints within the clinical trial timeline.
NODATA
Register for this webinar to learn key strategies to successfully conduct neuroscience clinical trials through lessons learned from how Medpace works to integrate clinical operations, medical monitoring, central lab and core lab experts.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
James Vornov, MD, PhD, Vice President, Medical Department, Medpace Danielle N. Caudell Stamper, MSN, AGACNP-BC Advanced Clinical Practitioner, Medpace Scott K. Holland, PhD, Sr. Director, Scientific Affairs, Medpace Core Labs Serena Allen, PhD, Principal Scientist, Medpace Central Labs
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -9-14
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|